Bioartificial organ support for hepatic, renal, and hematologic failure.
The current strategy to the treatment of SIRS and MODS uses a multidisciplinary approach that emphasizes supportive therapy. Herein, we have presented a futuristic approach that focuses on replacing the function of failed organs using bioartificial technology (Table 1). Bioartificial organ technology may allow the intensivist to provide physiologic organ replacement either as a bridge to transplantation or as a "time-buying" element until native organs that have become acutely dysfunctional or nonfunctional in a variety of clinical settings, can recover their function or regenerate their mass. As bioartificial organ technology matures, it is conceivable as an ultimate goal that non-immunogenic bioartificial organs would be miniaturized or redesigned and acutely placed within the intracorporeal space as replacement organs.
Maguire
P J
PJ
Department of Medical Affairs and New Technology Development, Vitagen Inc., La Jolla, California, USA.
Stevens
C
C
Humes
H D
HD
Shander
A
A
Halpern
N A
NA
Pastores
S M
SM
D021522:Bioartificial Organs / Q000639:trends*; D019149:Bioreactors; D001802:Blood Substitutes; D006801:Humans; D007688:Kidneys, Artificial / Q000639:trends*; D017093:Liver Failure / Q000628:therapy*; D019164:Liver, Artificial / Q000639:trends*; D051437:Renal Insufficiency / Q000628:therapy*
D001802:Blood Substitutes